Christopher S Tallarida1, Ronald J Tallarida1, Scott M Rawls2. 1. Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA. 2. Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA. Electronic address: scott.rawls@temple.edu.
Abstract
BACKGROUND: The Drug Enforcement Agency estimates that 80% of cocaine seized in the United States contains the veterinary pharmaceutical levamisole (LVM). One problem with LVM is that it is producing life-threatening neutropenia in an alarming number of cocaine abusers. The neuropharmacological profile of LVM is also suggestive of an agent with modest reinforcing and stimulant effects that could enhance cocaine's addictive effects. METHODS: We tested the hypothesis that LVM (ip) enhances the rewarding and locomotor stimulant effects of cocaine (ip) using rat conditioned place preference (CPP) and locomotor assays. Effects of LVM by itself were also tested. RESULTS: LVM (0-10 mg/kg) produced CPP at 1mg/kg (P<0.05) and locomotor activation at 5mg/kg (P < 0.05). For CPP combination experiments, a statistically inactive dose of LVM (0.1 mg/kg) was administered with a low dose of cocaine (2.5 mg/kg). Neither agent produced CPP compared to saline (P > 0.05); however, the combination of LVM and cocaine produced enhanced CPP compared to saline or either drug by itself (P < 0.01). For locomotor experiments, the same inactive dose of LVM (0.1mg/kg, ip) was administered with low (10 mg/kg) and high doses (30 mg/kg) of cocaine. LVM (0.1 mg/kg) enhanced locomotor activation produced by 10mg/kg of cocaine (P < 0.05) but not by 30 mg/kg (P>0.05). CONCLUSIONS: LVM can enhance rewarding and locomotor-activating effects of low doses of cocaine in rats while possessing modest activity of its own.
BACKGROUND: The Drug Enforcement Agency estimates that 80% of cocaine seized in the United States contains the veterinary pharmaceutical levamisole (LVM). One problem with LVM is that it is producing life-threatening neutropenia in an alarming number of cocaine abusers. The neuropharmacological profile of LVM is also suggestive of an agent with modest reinforcing and stimulant effects that could enhance cocaine's addictive effects. METHODS: We tested the hypothesis that LVM (ip) enhances the rewarding and locomotor stimulant effects of cocaine (ip) using rat conditioned place preference (CPP) and locomotor assays. Effects of LVM by itself were also tested. RESULTS:LVM (0-10 mg/kg) produced CPP at 1mg/kg (P<0.05) and locomotor activation at 5mg/kg (P < 0.05). For CPP combination experiments, a statistically inactive dose of LVM (0.1 mg/kg) was administered with a low dose of cocaine (2.5 mg/kg). Neither agent produced CPP compared to saline (P > 0.05); however, the combination of LVM and cocaine produced enhanced CPP compared to saline or either drug by itself (P < 0.01). For locomotor experiments, the same inactive dose of LVM (0.1mg/kg, ip) was administered with low (10 mg/kg) and high doses (30 mg/kg) of cocaine. LVM (0.1 mg/kg) enhanced locomotor activation produced by 10mg/kg of cocaine (P < 0.05) but not by 30 mg/kg (P>0.05). CONCLUSIONS:LVM can enhance rewarding and locomotor-activating effects of low doses of cocaine in rats while possessing modest activity of its own.
Authors: Robert Huber; Jules B Panksepp; Thomas Nathaniel; Antonio Alcaro; Jaak Panksepp Journal: Neurosci Biobehav Rev Date: 2010-12-21 Impact factor: 8.989
Authors: Rubing Zhao-Shea; Liwang Liu; Lindsey G Soll; Ma Reina Improgo; Erin E Meyers; J Michael McIntosh; Sharon R Grady; Michael J Marks; Paul D Gardner; Andrew R Tapper Journal: Neuropsychopharmacology Date: 2011-02-02 Impact factor: 7.853
Authors: Angela Wolford; Thomas S McDonald; Heather Eng; Steven Hansel; Yue Chen; Jonathan Bauman; Raman Sharma; Amit S Kalgutkar Journal: Drug Metab Dispos Date: 2012-03-05 Impact factor: 3.922
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: Oné R Pagán; Amanda L Rowlands; Angela L Fattore; Tamara Coudron; Kimberly R Urban; Apurva H Bidja; Vesna A Eterović Journal: Eur J Pharmacol Date: 2009-05-30 Impact factor: 4.432
Authors: Steven F Merkel; Roshanak Razmpour; Evan M Lutton; Christopher S Tallarida; Nathan A Heldt; Lee Anne Cannella; Yuri Persidsky; Scott M Rawls; Servio H Ramirez Journal: J Neurotrauma Date: 2016-06-07 Impact factor: 5.269
Authors: Florian Conrad; Sarah Hirsiger; Sebastian Winklhofer; Markus R Baumgartner; Philipp Stämpfli; Erich Seifritz; Susanne Wegener; Boris B Quednow Journal: J Psychiatry Neurosci Date: 2021-04-12 Impact factor: 6.186